http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2572605-T3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D253-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-0812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D253-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2012-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eac882e27f0f0e850ad2d25aecd8421
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be4880b193ceae27e76d1b6345d36aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19fc0a8a394a71196adf36d1972b3e6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34af450328dd7d686e4081d0dab88740
publicationDate 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-2572605-T3
titleOfInvention Morpholinylbenzotriazines for use in cancer therapy
abstract Compounds of the formula (I): ** Formula ** characterized in that: R1 represents Het1 or Ar; R2, R3, independently of each other, represent Y or OY, or together also represent -O- (CH2) n-; R4 represents A or (CH2) nOA; L represents -CR2R3-, a single bond, - (CH2) n-, -CH (Hal) -, -C (Hal) 2-, - (CH2) nCH (OY) -, - (CH2) nCO-, - (CH2) nNH-, - (CH2) nCONY2-, -NYCO-, -NHCO-NH-, -NR4CO-, -NYSO2-, -C (> = NR4) -, -C (> = NCN) -, - CY (NY2) -, -CY (CN) -, -CY (O- (CH2) nCN) -, -CY (Het2) - or -CY (O- (CH2) nHet2) -; Y represents H or A; A represents unbranched or branched alkyl having 1-10 C atoms, in which, independently of each other, 1-7 H atoms can be replaced by Hal; Cyc represents cyclic alkyl having 3-7 C atoms, in which, independently of each other, 1-4 H atoms can be replaced by Hal; Ar represents phenyl that is unsubstituted or mono- or disubstituted by Hal, (CH2) pOY, R4, (CH2) pOR4, COOY, NY2, NYCOY and / or CN; Het1 represents mono- or bicyclic heteroaryl having 2-9 atoms of C and 1-4 atoms of N, O and / or S, which can be unsubstituted or mono- or disubstituted by Hal, (CH2) pOY, R4, (CH2 ) pOR4,> = O, COOY, NY2, NYCOY, CONY2, Cyc, Het2 and / or CN; Het2 represents a monocyclic saturated heterocycle having 2-7 atoms of C and 1-4 atoms of N, O and / or S, which can be unsubstituted or monosubstituted by A; Hal represents F, Cl, Br or I; m represents 0, 1 or 2; and n, p, independently of each other, represent 0, 1, 2, 3, 4 or 5, and / or the physiologically acceptable salts, tautomers and / or stereoisomers thereof, including mixtures thereof in all ratios.
priorityDate 2011-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457516807
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393777
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71571152
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414422437
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71571302
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID89582517
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431144055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414513664

Total number of triples: 54.